579 related articles for article (PubMed ID: 23137512)
1. Quality of life and chronic heart failure therapy guided by natriuretic peptides: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study.
Bhardwaj A; Rehman SU; Mohammed AA; Gaggin HK; Barajas L; Barajas J; Moore SA; Sullivan D; Januzzi JL
Am Heart J; 2012 Nov; 164(5):793-799.e1. PubMed ID: 23137512
[TBL] [Abstract][Full Text] [Related]
2. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.
Sanders-van Wijk S; Maeder MT; Nietlispach F; Rickli H; Estlinbaum W; Erne P; Rickenbacher P; Peter M; Pfisterer MP; Brunner-La Rocca HP;
Circ Heart Fail; 2014 Jan; 7(1):131-9. PubMed ID: 24352403
[TBL] [Abstract][Full Text] [Related]
3. Design and methods of the Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study.
Bhardwaj A; Rehman SU; Mohammed A; Baggish AL; Moore SA; Januzzi JL
Am Heart J; 2010 Apr; 159(4):532-538.e1. PubMed ID: 20362709
[TBL] [Abstract][Full Text] [Related]
4. Adding serial N-terminal pro brain natriuretic peptide measurements to optimal clinical management in outpatients with systolic heart failure: a multicentre randomized clinical trial (NorthStar monitoring study).
Schou M; Gustafsson F; Videbaek L; Andersen H; Toft J; Nyvad O; Ryde H; Fog L; Jensen JC; Nielsen OW; Lind-Rasmussen S; Abdulla J; Hildebrandt PR;
Eur J Heart Fail; 2013 Jul; 15(7):818-27. PubMed ID: 23507787
[TBL] [Abstract][Full Text] [Related]
5. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency.
Toblli JE; Lombraña A; Duarte P; Di Gennaro F
J Am Coll Cardiol; 2007 Oct; 50(17):1657-65. PubMed ID: 17950147
[TBL] [Abstract][Full Text] [Related]
6. N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF).
Maeder MT; Rickenbacher P; Rickli H; Abbühl H; Gutmann M; Erne P; Vuilliomenet A; Peter M; Pfisterer M; Brunner-La Rocca HP;
Eur J Heart Fail; 2013 Oct; 15(10):1148-56. PubMed ID: 23657728
[TBL] [Abstract][Full Text] [Related]
7. Improvement in structural and functional echocardiographic parameters during chronic heart failure therapy guided by natriuretic peptides: mechanistic insights from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) study.
Weiner RB; Baggish AL; Chen-Tournoux A; Marshall JE; Gaggin HK; Bhardwaj A; Mohammed AA; Rehman SU; Barajas L; Barajas J; Gregory SA; Moore SA; Semigran MJ; Januzzi JL
Eur J Heart Fail; 2013 Mar; 15(3):342-51. PubMed ID: 23132825
[TBL] [Abstract][Full Text] [Related]
8. Safety and tolerability of intensified, N-terminal pro brain natriuretic peptide-guided compared with standard medical therapy in elderly patients with congestive heart failure: results from TIME-CHF.
Sanders-van Wijk S; Muzzarelli S; Neuhaus M; Kiencke S; Maeder M; Estlinbaum W; Tobler D; Mayer K; Erne P; Pfisterer ME; Brunner-La Rocca HP;
Eur J Heart Fail; 2013 Aug; 15(8):910-8. PubMed ID: 23666681
[TBL] [Abstract][Full Text] [Related]
9. Serial NT-proBNP monitoring and outcomes in outpatients with decompensation of heart failure.
Bayes-Genis A; Pascual-Figal D; Fabregat J; Domingo M; Planas F; Casas T; Ordoñez-Llanos J; Valdes M; Cinca J
Int J Cardiol; 2007 Sep; 120(3):338-43. PubMed ID: 17174423
[TBL] [Abstract][Full Text] [Related]
10. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial.
Lainchbury JG; Troughton RW; Strangman KM; Frampton CM; Pilbrow A; Yandle TG; Hamid AK; Nicholls MG; Richards AM
J Am Coll Cardiol; 2009 Dec; 55(1):53-60. PubMed ID: 20117364
[TBL] [Abstract][Full Text] [Related]
11. Characterization and prediction of adverse events from intensive chronic heart failure management and effect on quality of life: results from the pro-B-type natriuretic peptide outpatient-tailored chronic heart failure therapy (PROTECT) study.
Gandhi PU; Szymonifka J; Motiwala SR; Belcher AM; Januzzi JL; Gaggin HK
J Card Fail; 2015 Jan; 21(1):9-15. PubMed ID: 25463415
[TBL] [Abstract][Full Text] [Related]
12. Characterization and prediction of natriuretic peptide "nonresponse" during heart failure management: results from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) and the NT-proBNP-Assisted Treatment to Lessen Serial Cardiac Readmissions and Death (BATTLESCARRED) study.
Gaggin HK; Truong QA; Rehman SU; Mohammed AA; Bhardwaj A; Parks KA; Sullivan DA; Chen-Tournoux A; Moore SA; Richards AM; Troughton RW; Lainchbury JG; Weiner RB; Baggish AL; Semigran MJ; Januzzi JL
Congest Heart Fail; 2013; 19(3):135-42. PubMed ID: 23279139
[TBL] [Abstract][Full Text] [Related]
13. N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study.
Berger R; Moertl D; Peter S; Ahmadi R; Huelsmann M; Yamuti S; Wagner B; Pacher R
J Am Coll Cardiol; 2010 Feb; 55(7):645-53. PubMed ID: 20170790
[TBL] [Abstract][Full Text] [Related]
14. Effect of beta-blockade and ACE inhibition on B-type natriuretic peptides in stable patients with systolic heart failure.
Rosenberg J; Gustafsson F; Remme WJ; Riegger GA; Hildebrandt PR
Cardiovasc Drugs Ther; 2008 Aug; 22(4):305-11. PubMed ID: 18309461
[TBL] [Abstract][Full Text] [Related]
15. Heart failure outcomes and benefits of NT-proBNP-guided management in the elderly: results from the prospective, randomized ProBNP outpatient tailored chronic heart failure therapy (PROTECT) study.
Gaggin HK; Mohammed AA; Bhardwaj A; Rehman SU; Gregory SA; Weiner RB; Baggish AL; Moore SA; Semigran MJ; Januzzi JL
J Card Fail; 2012 Aug; 18(8):626-34. PubMed ID: 22858078
[TBL] [Abstract][Full Text] [Related]
16. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.
von Haehling S; Jankowska EA; Morgenthaler NG; Vassanelli C; Zanolla L; Rozentryt P; Filippatos GS; Doehner W; Koehler F; Papassotiriou J; Kremastinos DT; Banasiak W; Struck J; Ponikowski P; Bergmann A; Anker SD
J Am Coll Cardiol; 2007 Nov; 50(20):1973-80. PubMed ID: 17996563
[TBL] [Abstract][Full Text] [Related]
17. Effects of ivabradine therapy on heart failure biomarkers.
Ordu S; Yildiz BS; Alihanoglu YI; Ozsoy A; Tosun M; Evrengul H; Kaftan HA; Ozhan H
Cardiol J; 2015; 22(5):501-9. PubMed ID: 25733317
[TBL] [Abstract][Full Text] [Related]
18. The Importance of Worsening Heart Failure in Ambulatory Patients: Definition, Characteristics, and Effects of Amino-Terminal Pro-B-Type Natriuretic Peptide Guided Therapy.
Mallick A; Gandhi PU; Gaggin HK; Ibrahim N; Januzzi JL
JACC Heart Fail; 2016 Sep; 4(9):749-55. PubMed ID: 27179830
[TBL] [Abstract][Full Text] [Related]
19. Association between psychological measures and brain natriuretic peptide in heart failure patients.
Brouwers C; Spindler H; Larsen ML; Eiskær H; Videbæk L; Pedersen MS; Aagard B; Pedersen SS
Scand Cardiovasc J; 2012 Jun; 46(3):154-62. PubMed ID: 22251274
[TBL] [Abstract][Full Text] [Related]
20. Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction.
Januzzi JL; Rehman SU; Mohammed AA; Bhardwaj A; Barajas L; Barajas J; Kim HN; Baggish AL; Weiner RB; Chen-Tournoux A; Marshall JE; Moore SA; Carlson WD; Lewis GD; Shin J; Sullivan D; Parks K; Wang TJ; Gregory SA; Uthamalingam S; Semigran MJ
J Am Coll Cardiol; 2011 Oct; 58(18):1881-9. PubMed ID: 22018299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
